J P Morgan Chase & Co set a €100.00 ($117.65) price target on Merck KGaA (FRA:MRK) in a research note issued to investors on Wednesday. The brokerage currently has a neutral rating on the healthcare company’s stock.

MRK has been the subject of several other reports. HSBC Holdings plc set a €94.00 ($110.59) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Wednesday, August 9th. Independent Research GmbH set a €105.00 ($123.53) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Wednesday, September 6th. Kepler Capital Markets set a €115.00 ($135.29) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Wednesday, October 4th. Berenberg Bank set a €116.00 ($136.47) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Tuesday, September 19th. Finally, Citigroup Inc. set a €123.00 ($144.71) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Monday, September 25th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of €109.17 ($128.44).

Merck KGaA (MRK) opened at €92.61 ($108.95) on Wednesday. Merck KGaA has a 52 week low of €89.00 ($104.71) and a 52 week high of €115.00 ($135.29).

ILLEGAL ACTIVITY NOTICE: “Merck KGaA (MRK) Given a €100.00 Price Target at J P Morgan Chase & Co” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/merck-kgaa-mrk-given-a-100-00-price-target-at-j-p-morgan-chase-co/1679873.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.